Categories: All postsCannabis

HEXO is an elite cannabis producer, Beacon Securities says

The market may have missed a major milestone passed by cannabis company HEXO Corp. (HEXO Stock Quote, Chart TSX:HEXO), according to Russell Stanley, analyst for Beacon Securities, who on Monday reiterated his “Buy” rating and $11.00 target price.

On December 27, Gatineau, Quebec’s HEXO announced the completion of the first phase of its one-million sq. ft. greenhouse expansion, saying that the construction has been completed on time and on budget and is now licensed and ready for plants to move in.

“Receiving initial licensing on our 1,000,000 sq. ft. facility is a huge accomplishment for the entire HEXO team,” said Sébastien St. Louis, HEXO Corp’s CEO and cofounder in a press release. “The new production facility allows us to continue to scale-up which, once fully operational, will give customers across Canada access to HEXO products.”

Stanley says the construction puts HEXO on its way to reaching 108,000 kg per year but that the announcement may have been overlooked due to timing over the holidays. Another December announcement was that HEXO had filed an application to list on the NYSE exchange, and with only five cannabis companies currently with US listings, Stanley says that the NYSE listing should benefit HEXO on scarcity value alone.

“We continue to view HEXO as an elite cannabis producer, combining large scale/low cost production capacity with demonstrated strength in commercializing unique value-added products. This positions HEXO has an attractive candidate for a strategic investor (or acquirer), and a NYSE-listing should significantly increase the company’s profile in that context,” Stanley says.

At 10x his 2020 EBITDA estimates, Stanley values HEXO at a 41 per cent discount to its broader peer group at 16x and at a 72 per cent discount to the larger cannabis group (above $1 million market cap) which is valued at 35x 2020 estimates.

The analyst’s $11.00 target represents a projected 12-month return of 89 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: hexo
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

5 hours ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

7 hours ago

OpenText price target cut at National Bank

Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]

8 hours ago

Silicon Motion stock still a buy, Roth says

Following the company's first quarter results, Roth MKM analyst Suji Desilava remains bullish on Silicon Motion Technology (Silicon Motion Technology… [Read More]

9 hours ago

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

3 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

3 days ago